Sleep disorders commonly occur in patients with ankylosing spondylitis (AS), particularly those with high disease activity, a study has found. Furthermore, treatment with antitumour necrosis factor (anti-TNF)-α improves sleep quality but not polysomnography parameters.
Targeting mast cells with imatinib, which inhibits the receptor tyrosine kinase KIT, may decrease airway hyperresponsiveness and improve symptoms in patients with severe, poorly controlled asthma, according to a proof-of-principle clinical trial.
The risk of respiratory syncytial virus hospitalization (RSVH) and respiratory-related illness hospitalization (RIH) does not significantly differ between the first and second year of life in paediatric patients with haemodynamically significant congenital heart disease (HSCHD), a new study shows.
The fully-human immunocytokine dekavil (also known as F8-IL10) has demonstrated signs of safety and efficacy in patients with active rheumatoid arthritis (RA) in a phase I study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017.
The risk of cardiovascular morbidity is reduced in elderly patients who highly adhere to antihypertensive drug therapy, reports a new study. Furthermore, adherence to antihypertensives also lowers the risk of heart failure and stroke, but not myocardial infarction (MI), and extending to all-cause death.
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.
Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.
New drug applications approved by US FDA as of 1 - 15 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.